急诊PCI时应用替罗非班的临床观察被引量：10

下载PDF

导出

摘要目的观察急诊冠脉内支架植入术时应用替罗非班,对前向血流TIMI分级情况及血小板活化功能的影响。方法选取急性ST段抬高性心肌梗死58例患者,按在急诊室是否应用替罗非班分为:常规用药组(未用替罗非班,n=23)及替罗非班组(应用替罗非班,n=35)。观察前向血流TIMI分级情况及服药前和服药后3d对血小板活化标志物的影响。结果替罗非班组微血管灌注改善,PCI术后无复流和慢血流现象减少,明显提高TIMI血流分级,而且对血小板活化标志物CD63,CD62p的抑制作用明显优于常规药物治疗组(P<0.05)。结论急诊PCI患者加用盐酸替罗非班可以改善TIMI血流分级,对血小板活化功能抑制优于常规药物治疗。

作者李波张利华杨欣国任引刚王子宽张录兴

机构地区第四军医大学唐都医院心血管内科

出处《山西医科大学学报》 CAS 2010年第6期530-531,共2页 Journal of Shanxi Medical University

关键词替罗非班急诊PCI 血流分级血小板

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1沈杰,沈卫峰.替罗非班在急性冠脉综合征介入治疗中的应用[J].国际心血管病杂志,2006,33(3):156-159. 被引量：72
2Tanaka A,Kawarabayashi T,Nishibori Y,et al.No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction[J].Circulation,2002,105:2148-2152.
3Resnic FS,Wainstein M,Lee MK,et al.No-reflow is an indepen-dent predictor of death and myocardial infarction after percutaneous cornary intervention[J].Am Heart J,2003,145:42-46.
4Sedlmayr P,Grobbaupt B,Muntean W.Flow cytometyic detective of intracellular platelet antigens[J].Cytometry,1996,23:284-289.
5Michelson AD,Barmard MR,Krueger LA,et al.Evaluation of platelet function by flow cytometry[J].Methods,2000,21:259-270.
6Petronio AS,De Carlo M,Ciabatti N,et al.Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine[J].Am Heart J,2005,150(5):1015.

二级参考文献19

1[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
2[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.
3[3]Heitzer,T Ollmann,I Koke,K et al.Platelet Glycoprotein Ⅱb/Ⅲa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease[J].Circulation,2003,108 (5):536-541.
4[4]Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95 (1):20-23
5[5]De Luca G,Smit JJ,Ernst N,et al.Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction[J].Thromb Haemost,2005,93 (5):820-823.
6[6]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in STelevation acute myocardial infarction[J].Am J Cardiol,2004,93 (3):280-287.
7[7]Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GP Ⅱb/Ⅲa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients[J].J Invasive Cardiol,2005,17 (6):296-299.
8[8]Roffi M,Chew DP,Mukherjee D,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibition in acute coronary syndromes.Gradient of benefit related to the revascularization strategy[J].Eur Heart J,2002,23 (18):1441-1448.
9[9]Sabatine MS,Morrow DA,Giugliano RP,et al.Implications of upstream glycoprotein Ⅱb/Ⅲa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction:a comparison of the Thrombolysis In Myocardial Infarction (TIMI) ⅢB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial[J].Circulation,2004,109 (7):874-880.
10[10]Marsh JD.Early use of glycoprotein Ⅱb/Ⅲa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes[J].Am J Health Syst Pharm,2002,59 (21 Suppl 7):S15-S26.